MARKET

ZBIO

ZBIO

Zenas BioPharma Inc.
NASDAQ
8.31
-0.42
-4.81%
Opening 13:08 03/14 EDT
OPEN
8.84
PREV CLOSE
8.73
HIGH
9.08
LOW
8.25
VOLUME
108.90K
TURNOVER
--
52 WEEK HIGH
26.25
52 WEEK LOW
5.83
MARKET CAP
347.35M
P/E (TTM)
-0.6987
1D
5D
1M
3M
1Y
5Y
1D
Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?
Simply Wall St · 1d ago
Zenas BioPharma Price Target Maintained With a $45.00/Share by Guggenheim
Dow Jones · 2d ago
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $45 Price Target
Benzinga · 2d ago
Zenas BioPharma Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target
Benzinga · 2d ago
Weekly Report: what happened at ZBIO last week (0303-0307)?
Weekly Report · 4d ago
Adobe, DICK's Sporting Goods, Dollar General To Report Results As Investors Look To Inflation Report
Seeking Alpha · 6d ago
Weekly Report: what happened at ZBIO last week (0224-0228)?
Weekly Report · 03/03 12:51
More
About ZBIO
More
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Recently
Symbol
Price
%Change

Webull offers Zenas BioPharma Inc. stock information, including NASDAQ: ZBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZBIO stock methods without spending real money on the virtual paper trading platform.